Association between the TGFBR2 G-875A Polymorphism and Cancer Risk: Evidence from a Meta-analysis

  • Huang, Yong-Sheng (Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences) ;
  • Zhong, Yu (The State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University) ;
  • Yu, Long (The State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University) ;
  • Wang, Lin (Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences)
  • Published : 2014.11.06


Disrupted transforming growth factor-${\beta}$ (TGF-${\beta}$) signaling is involved in the development of various types of cancer and the TGF-${\beta}$ receptor II (TGFBR2) is a key mediator of TGF-${\beta}$ growth inhibitory signals. It is reported that the G-875A polymorphism in TGFBR2 is implicated in risk of various cancers. However, results for the association between this polymorphism and cancer remain conflicting. To derive a more precise estimation, a meta-analysis of 3,808 cases and 4,489 controls from nine published case-control studies was performed. Our analysis indicated that G-875A is associated with a trend of decreased cancer risk for allele A versus(vs.) allele G [odds ratio (OR) =0.64, 95% confidence intervals (CI): 0.55-0.74], as well as for both dominant model [(A/A+G/A) vs. G/G, OR=0.76, 95% CI: 0.64-0.90] and recessive model [A/A vs. (G/G+G/A), OR=0.74, 95% CI: 0.59-0.93). However, larger scale primary studies are required to further evaluate the interaction of TGFBR2 G-875A polymorphism and cancer risk in specific cancer subtypes.


  1. Adorno M, Cordenonsi M, Montagner M, et al (2009). A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell, 137, 87-98.
  2. Derynck R, Akhurst RJ, Balmain A (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet, 29, 117-29.
  3. Derynck R, Zhang YE (2003). Smad-dependent and Smadindependent pathways in TGF-beta family signalling. Nature, 425, 577-84.
  4. Guo W, Dong Z, Guo Y, et al (2012). Association of polymorphisms in transforming growth factor-beta receptors with susceptibility to gastric cardia adenocarcinoma. Mol Biol Rep, 39, 4301-9.
  5. Huang Y, Hao Y, Li B, et al (2011). Lack of significant association between TGF-beta1-590C/T polymorphism and breast cancer risk: a meta-analysis. Med Oncol, 28, 424-8.
  6. Huang Y, Li B, Qian J, et al (2010). TGF-beta1 29T/C polymorphism and breast cancer risk: a meta-analysis involving 25, 996 subjects. Breast Cancer Res Treat, 123, 863-8.
  7. Jin Q, Hemminki K, Grzybowska E, et al (2004). Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer, 112, 94-9.
  8. Ikushima H, Miyazono K (2010). TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer, 10, 415-24.
  9. Jin G, Deng Y, Miao R, et al (2008). TGFB1 and TGFBR2 functional polymorphisms and risk of esophageal squamous cell carcinoma: a case-control analysis in a Chinese population. J Cancer Res Clin Oncol, 134, 345-51.
  10. Jin G, Wang L, Chen W, et al (2007). Variant alleles of TGFB1 and TGFBR2 are associated with a decreased risk of gastric cancer in a Chinese population. Int J Cancer, 120, 1330-5.
  11. Li Z, Zhang LJ, Zhang HR, et al (2014). Tumor-derived transforming growth factor-beta is critical for tumor progression and evasion from immune surveillance. Asian Pac J Cancer Prev, 15, 5181-6.
  12. Liu Y, Lin XF, Lin CJ, et al (2012). Transforming growth factor beta-1 C-509T polymorphism and cancer risk: a metaanalysis of 55 case-control studies. Asian Pac J Cancer Prev, 13, 4683-8.
  13. Massague J (2008). TGFbeta in cancer. Cell, 134, 215-30.
  14. Massague J (2012a). TGF-beta signaling in development and disease. FEBS Lett, 586, 1833.
  15. Massague J (2012b). TGFbeta signalling in context. Nat Rev Mol Cell Biol, 13, 616-30.
  16. Schmierer B, Hill CS (2007). TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol, 8, 970-82.
  17. Seijo ER, Song H, Lynch MA, et al (2001). Identification of genetic alterations in the TGFbeta type II receptor gene promoter. Mutat Res, 483, 19-26.
  18. Teixeira AL, Gomes M, Nogueira A, et al (2013). Improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in TGFbeta1 signaling pathway modulation. PLoS One, 8, 72419.
  19. Wu MY, Hill CS (2009). Tgf-beta superfamily signaling in embryonic development and homeostasis. Dev Cell, 16, 329-43.
  20. Xu L, Zeng Z, Chen B, et al (2011). Association between the TGFB1 -509C/T and TGFBR2 -875A/G polymorphisms and gastric cancer: a case-control study. Oncol Lett, 2, 371-7.
  21. Zhang M, Guo L, Cheng Z, et al (2011). A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER (+), PR (+), ER (+)PR (+) and HER2 (-) expression in women. Oncol Lett, 2, 653-8.
  22. Zhou Y, Jin GF, Jiang GJ, et al (2007). Correlations of polymorphisms of TGFB1 and TGFBR2 genes to genetic susceptibility to gastric cancer. Ai Zheng, 26, 581-5.

Cited by

  1. MicroRNA-19a promotes nasopharyngeal carcinoma by targeting transforming growth factor β receptor 2 vol.14, pp.2, 2017,